Table 4 Comparison of resistance indicator candidates for six anticancer drugs in SNU-267 cells
| Â | Sunitinib | Axitinib | Pazopanib | Sorafenib | Everolimus | Temsirolimus | |
|---|---|---|---|---|---|---|---|
IC50 | Control | 5.66 | 7.49 | 4.91 | 6.46 | 8.22 | 11.64 |
Resistant cells | 5.48 (0.97) | 1.5 (0.20) | 3.75 (0.76) | 6.34 (0.98) | 0.008 (< 0.01) | 0.008 (< 0.01) | |
Reversible | 5.61 (0.99) | 1.93 (0.26) | 3.51 (0.71) | 6.71 (1.04) | 0.33 (0.04) | 0.01 (< 0.01) | |
GI50 | Control | 4.28 | 0.92 | 0.97 | 3.19 | 0.06 | 0.07 |
Resistant cells | 5.1 (1.19) | 1.14 (1.24) | 1.92 (1.98) | 5.59 (1.75) | 0.007 (0.12) | 0.006 (0.09) | |
Reversible | 5.08 (1.19) | 1.7 (1.85) | 2.65 (2.73) | 5.97 (1.87) | 0.009 (0.15) | 0.008 (0.11) | |
GR50 | Control | 4.27 | 1.68 | 1.28 | 4.25 | 0.86 | 2.58 |
Resistant cells | 5.41 (1.27) | 1.62 (0.96) | 3.06 (2.39) | 6.11 (1.44) | 0.009 (0.01) | 0.01 (< 0.01) | |
Reversible | 5.57 (1.30) | 1.72 (1.02) | 3.46 (2.70) | 6.7 (1.58) | 0.009 (0.01) | 0.0103 (< 0.01) | |
GI100 | Control | 5.45 | 13.15 | 9.45 | 7.67 | 15.02 | 18.92 |
Resistant cells | 9.12 (1.67) | 17.9 (1.36) | 13.85 (1.47) | 8.71 (1.14) | 20.2 (1.34) | 20.6 (1.09) | |
Reversible | 9.75 (1.79) | 16.85 (1.28) | 17.75 (1.88) | 9.43 (1.23) | 22.05 (1.47) | 19.9 (1.05) | |
GR100 | Control | 5.46 | 12.96 | 11.81 | 7.67 | 15.01 | 19.02 |
Resistant cells | 9.29 (1.70) | 18.08 (1.40) | 13.67 (1.16) | 8.82 (1.15) | 20.29 (1.35) | 20.28 (1.07) | |
Reversible | 9.73 (1.78) | 18.11 (1.40) | 16.46 (1.39) | 9.37 (1.22) | 21.81 (1.45) | 19.85 (1.04) | |